XML 159 R82.htm IDEA: XBRL DOCUMENT v3.26.1
Non-controlling interests (Tables)
 12 Months Ended
Dec. 31, 2025
Non-controlling interests [Abstract]  
Summary of non-controlling interests for continuing and discontinued operations
The non-controlling interests were based on the following data:
202520242023
(Loss)/profit attributable to non-controlling interests
 - from continuing operations$(1,711)$832 $(429)
 - from discontinued operations(558)(4,334)(1,624)
$(2,269)$(3,502)$(2,053)
Total comprehensive (expenses)/income attributable to non-controlling interests
 - from continuing operations$(1,711)$832 $(429)
 - from discontinued operations(492)(4,574)(1,441)
$(2,203)$(3,742)$(1,870)
Summary of the group's material non-controlling interests
The following list contains the material subsidiaries of the Group at December 31, 2025 and 2024 are as follows:
Name of subsidiaries
Place of
incorporation/
operation
Issued and
fully paid
share capital
Proportion of nominal value of
issue capital held by the Company		Principal activities
20252024 
DirectlyIndirectlyDirectlyIndirectly 
%%%% 
Prenetics LimitedHong KongHK$415,276,716— 100 — 100 Genetic and diagnostic health testing
Europa Partners Holdings, LLC (note 33)The United StatesGBP11.00— 100 — 100 Provision of fulfillment and distribution services of sports nutrition products
IM8 Group Holding CompanyCayman Islands$1100 — 100 — 
Sales of consumer health products
IM8 (US) LLCThe United Statesn/a100 — 100 — 
Sales of consumer health products
IM8 LimitedHong KongHK$1100 — 100 — 
Sales of consumer health products
ACT Genomics Holdings Company LimitedCayman Islands$16,713— — 73.27 — Precise cancer genetic testing services
ACT Genomics Co., Ltd.TaiwanTWD455,080,000— — — 73.21 Precise cancer genetic testing - services
ACT Genomics (Hong Kong) LimitedHong KongHK$775,000— — — 73.27 Precise cancer genetic testing - services
Sanomics LimitedHong KongHK$500,000— — — 73.27 Precise cancer genetic testing - services
MC Diagnostics LimitedUnited KingdomGBP1,164— — — 73.27 Sales of medical diagnostics products
The following table summaries the information relating each of the Group's subsidiaries that has material non-controlling interests, before any intra-group eliminations.
As at October 1, 2025As at December 31, 2024
ACT Genomics
Non-controlling interests percentage26.73 %26.73 %

As at October 1, 2025As at December 31, 2024
Non-current assets$44,120 $27,549 
Current assets7,380 13,304 
Non-current liabilities(3,128)(4,297)
Current liabilities(5,353)(7,797)
Equity attributable to equity shareholder of the parent Company44,187 21,072 
Equity attributable to non-controlling interests(1,168)7,687 
January 1, 2025 to October 1, 2025January 1, 2024 to December 31, 2024
Revenue$12,471 $17,653 
Expenses(21,240)(30,413)
Loss for the year$(8,769)$(12,760)
Loss attributable to equity shareholder of the parent Company$(6,425)$(9,397)
Loss attributable to non-controlling interests(2,344)(3,363)
Loss for the year$(8,769)$(12,760)
Other comprehensive income/(expense) attributable to equity shareholder of the parent Company$184 $(574)
Other comprehensive income/(expense) attributable to non-controlling interests66 (210)
Other comprehensive income/(expense) for the year$250 $(784)
Total comprehensive expense attributable to equity shareholder of the parent Company$(6,241)$(9,971)
Total comprehensive expense attributable to non-controlling interests(2,278)(3,573)
Total comprehensive expense for the year$(8,519)$(13,544)
Net cash (outflow)/inflow from operating activities$(3,536)$5,483 
Net cash outflow from investing activities(238)(318)
Net cash outflow from financing activities(961)(1,413)
Net cash (outflow)/inflow$(4,735)$3,752 
Dividends paid to non-controlling interests$— $—